Problem Solving: What’s the Best Approach?

June 20, 2016

Those of you in the pharmaceutical, biotech and medical device industries who encounter process and product problems on a regular basis, you likely grimace when one lands in your lap. There is a degree of dread associated with a problem solving requirement as it represents a diversion from other pressing matters and will require effort you hadn't necessarily budgeted for yourself. Indeed, effective problem solving takes time and attention; but that's generally a small investment compared to the impact and ramifications of a serious problem not solved.

So, the reality being what it is, what is the best approach to problem solving? That's a rhetorical question for sure as there's not a one-size-fits-all answer; however, one can form a foundation of problem solving skills and techniques that can be tweaked to fit the specific nature of the problem at hand.

The table below lists the step-by-step approaches used in 3 different disciplines: Six-Sigma, CAPA and Risk Management. Although terminology differs slightly, notice how very similar each discipline utilizes essentially the same problem solving approach: problem identification (Houston, we have a problem!), evaluation (how bad is the problem?), investigation (what caused the problem?), resolution (how do we fix the problem?), improve (what's the plan for fixing the problem?), and verification of the effectiveness of the implemented remediation plan (did we truly fix the problem?).

As mentioned, there is not a universally accepted problem solving approach, especially one that will guarantee the problem will be solved effectively every time. However, one could do worse by not using the industry accepted, best-practice approaches used by those who are six-sigma, CAPA and Risk Management experts.


Learn more about ProPharma's Compliance services. Contact us to get in touch with our subject matter experts for a customized presentation.

TAGS:

March 9, 2021

What It Takes to Be Successful with GDUFA in 2021

GDUFA II was signed into law in 2017 effectively reauthorizing GDUFA I for fiscal years 2018 through 2022. The continuing goal of the amendment is to facilitate timely access to high-quality,...

August 17, 2016

cGMP for Phase 1 Investigational Drugs: Sterile Parenteral Drug Product Manufacturing

As Phase I clinical trials mark the first time that an investigational new drug is administered to humans, these studies are subject to appropriate current Good Manufacturing Practices (cGMP) in...

June 16, 2015

FDA Issues Final Guidance on Providing Regulatory Submission in Electronic Format – The eCTD Mandate is Coming

On May 5, 2015, the Food and Drug Administration (FDA) released the final guidance on Providing Regulatory Submissions in electronic format. The guidance implements the electronic submission...